Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New MRI techniques could sharpen view of MS brain damage

NCT ID NCT07245589

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to create better MRI methods for looking at the brains of people with multiple sclerosis (MS). Researchers will test these methods on 272 healthy volunteers and MS patients using both standard (3 Tesla) and ultra-high-field (7 Tesla) MRI machines. The goal is to make scans faster, more reliable, and better at detecting MS-related changes, which could help doctors diagnose and track the disease more accurately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 272 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 52 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For healthy volunteers : * Male or female aged 20 to 50 * Subject with no history of previous or concomitant neurological and psychiatric diseases at the time of inclusion * Subject without a history of traumatic brain injury * Subject with no vascular history (arterial hypertension, stroke) or concomitant at the time of its inclusion * Subject has no history of chronic drug and/or alcohol abuse * Subject having received information regarding the study and having signed an informed consent * Beneficiary or entitled person to a social security scheme * For MS patients * Male or female aged 18 to 52 * Patient diagnosed with MS according to the * criteria of McDonald 2017 * Patient presenting a maximum EDSS of 6 * Patient with MS for less than 10 years of evolution * Patient having received information regarding the study and having signed an informed consent * Patient beneficiary or entitled to a plan of social security Exclusion Criteria: * For healthy subjects : * Subject presenting a contraindication to performing an MRI: pacemaker, presence of metal implants, claustrophobia. * Subject unable to maintain a supine position for a prolonged period * Subject in a period of exclusion from another research protocol at the time of signing consent/non-opposition form * Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patient, adult patient under guardianship or curatorship, patient deprived of liberty, pregnant or breastfeeding woman) * For MS patients * Subject presenting a contraindication to performing an MRI: pacemaker, presence of metal implants, claustrophobia. * Subject unable to maintain a supine position for a prolonged period * Subject in a period of exclusion from another research protocol at the time of signing consent/non-opposition form * Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patient, adult patient under guardianship or curatorship, patient deprived of liberty, pregnant or breastfeeding woman)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Gui de Chauliac

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.